Skip to main content
Premium Trial:

Request an Annual Quote

NanoInk Begins Offering Dried Blood Spot Analysis for Protein Biomarker Research

Premium

Nanotechnology firm NanoInk said this week that it has begun offering dried blood spot analysis for protein biomarker research on a contract services basis.

The company will use its NanoArray Assay System for the detection, identification, and quantification of clinically relevant protein biomarkers from samples collected on dried blood spots via finger-stick blood draws.

DBS samples are minimally invasive, low-cost, and require little equipment to obtain, but because they contain only a small amount of sample, they are often unsuitable for analysis of low-abundance proteins via conventional immunoassays like ELISAs.

According to NanoInk, the NanoArray Assay System is capable of working with sample volumes as low as 2 µL and can detect proteins in the sub-picogram per mL range, making it well-suited to DBS analysis.

In a recently completed study, the platform demonstrated the ability to detect four clinically relevant cytokines – IL-1β, IL-4, IL-6, and TNF-α – at the single picogram per mL level in sample volumes between 4 and 5 µL, the company said.

The NanoArray Assay System is based on the company's dip pen nanolithography-fabrication technique, which uses sharp probes to spot biomolecules onto a surface.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.